Impact of Inhibition of Thrombocyte Activation on the course of chronic Hepatitis C.

Trial Profile

Impact of Inhibition of Thrombocyte Activation on the course of chronic Hepatitis C.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Aspirin (Primary) ; Cilostazol (Primary) ; Clopidogrel (Primary) ; Dabigatran etexilate (Primary)
  • Indications Embolism and thrombosis; Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top